Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nuvocid® (Oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI)

NCT00514527 is registered in ClinicalTrials.gov with Targanta Therapeutics Corporation as lead sponsor.

NCT NCT00514527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00514527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nuvocid® (Oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI)
Lead sponsor
Targanta Therapeutics Corporation
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
May 31, 2008
Enrollment
294 (estimated)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

abscess, cellulitis, staphylococcal skin infections, streptococcal infections, wounds and injuries